Mats Jerkeman

191 – 200 of 200

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/960ac58f-efc9-4246-b2b3-22c9226a529e?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
…
17
18
19
20
next »

2003
Mark Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study.
Linderoth, Johan ^LU ; Jerkeman, Mats ^LU ; Cavallin-Ståhl, Eva ^LU ; Kvaløy, Stein and Torlakovic, Emina (2003) In Clinical Cancer Research 9(2). p.722-728
- Contribution to journal › Article
2002
Mark Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman, Mats ^LU ; Aman, P ; Cavallin-Ståhl, Eva ^LU ; Torlakovic, E ; Åkerman, Måns ^LU ; Mitelman, Felix ^LU and Fioretos, Thoas ^LU (2002) In International Journal of Oncology 20(1). p.161-165
- Contribution to journal › Article
2001
Mark Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
Messori, A ; Vaiani, M ; Trippoli, S ; Rigacci, L ; Jerkeman, Mats ^LU and Longo, G (2001) In British Journal of Cancer 84(3). p.303-307
- Contribution to journal › Article
Mark Expression of the B-cell transcription factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-cell lymphoma (DLBCL)
Torlakovic, E ; Linderoth, J ; Jerkeman, Mats ^LU ; Kvaloy, S and Delabie, J (2001) In Blood 98(11). p.330-330
- Contribution to journal › Article
Mark Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial
Jerkeman, Mats ^LU ; Kaasa, S ; Hjermstad, M ; Kvaloy, S and Cavallin-Ståhl, Eva ^LU (2001) In Medical Oncology 18(1). p.85-94
- Contribution to journal › Article
2000
Mark Residual mass in aggressive lymphoma--does size, measured by computed tomography, influence clinical outcome?
Rodriguez-Catarino, M ; Jerkeman, Mats ^LU ; Ahlstrom, H ; Glimelius, B and Hagberg, H (2000) In Acta Oncologica 39(4). p.485-489
- Contribution to journal › Article
Mark Aggressive lymphoma
Jerkeman, Mats ^LU (2000)
- Thesis › Doctoral thesis (compilation)
1999
Mark Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas
Jerkeman, Mats ^LU ; Johansson, Bertil ^LU ; Åkerman, Måns ^LU ; Cavallin-Ståhl, Eva ^LU ; Kristoffersson, Ulf ^LU and Mitelman, Felix ^LU (1999) In European Journal of Haematology 62(3). p.184-190
- Contribution to journal › Article
Mark CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
Jerkeman, Mats ^LU ; Anderson, Harald ^LU ; Cavallin-Ståhl, Eva ^LU ; Dictor, Michael ^LU ; Hagberg, H ; Johnson, A ; Kaasa, S ; Kvaloy, S ; Sundstrom, C and Åkerman, Måns ^LU (1999) In Annals of Oncology 10(9). p.1079-1086
- Contribution to journal › Article
1992
Mark Bacteremic and non-bacteremic febrile urinary tract infection--a review of 168 hospital-treated patients
Jerkeman, Mats ^LU and Braconier, Jean Henrik ^LU (1992) In Infection 20(3). p.143-145
- Contribution to journal › Article

« previous
1
2
…
17
18
19
20
next »